Previous 10 | Next 10 |
Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The resilient U.S. stock market racked up another round of record highs on Friday, as investors looked past disappointing quarterly results f...
Gainers: G Medical Innovations (NASDAQ:GMVD) +15%, Accuray (NASDAQ:ARAY) +14%, Xeris Biopharma (NASDAQ:XERS) +9%, DURECT (NASDAQ:DRRX) +9%, Ocugen (NASDAQ:OCGN) +7%. Losers: CareDx (NASDAQ:CDNA) -25%, 4D Molecular Therapeutics (NASDAQ:FDMT) -2...
Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...
Shares of Rafael Holdings (NYSE: RFL) are tanking after its subsidiary Rafael Pharmaceuticals reported disastrous news for its experimental new cancer therapy. Investors caught off guard by a pair of clinical trial failures have hammered the stock 80% lower as of 10:45 a.m. EDT on T...
Gainers: HCW Biologics HCWB +115%, InflaRx IFRX +40%, Inspira Technologies Oxy (NASDAQ:IINN) +37%, Community Health Systems (NYSE:CYH) +16%, Invacare (NYSE:IVC) +11%. Losers: Rafael RFL -80%, DBV Technologies (NASDAQ:DBVT) -13%, Alny...
Rafael Holdings (NYSE:RFL) -76% after devimistat fails main goal in late-stage adenocarcinoma trial. Siyata Mobile (NASDAQ:SYTA) -22%. Futu Holdings (NASDAQ:FUTU) -20% after China warns on unlicensed online brokerages. UP Fintech Holding (NASDAQ:TIGR) -18% after ...
CRANBURY, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced that the AVENGER 500 Phase 3 clinical trial evaluating ...
Rafael Holdings (NYSE:RFL) shares plummeted more than 70% premarket after the company's CPI-613 (devimistat) failed to meet the primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the pancreas in a late-stage t...
Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy ...
News, Short Squeeze, Breakout and More Instantly...
Rafael Holdings Inc. Class B Company Name:
RFL Stock Symbol:
NYSE Market:
Rafael Holdings Inc. Class B Website:
NEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. “We remain committed to strategically and opportunistically deployi...
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet allows us to continue to fund our pipeline assets ...
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our real estate asset located in N...